- insufficient civil act capacity. - subjects at high risk of sars-cov-2 infection. - subject is/has ever had any acute or chronic medical condition, including but not limited to: - have any inflammatory disease, respiratory tract infection, have any respiratory symptoms such as: cough, sore throat, difficulty breathing, wheezing due to respiratory symptoms within 07 days before screening. fever (armpit temperature ≥ 37°c) for 3 days before vaccination. - history of any chronic respiratory illness such as bronchial asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease (copd). - malignant disease - immune disorders, using immunosuppressive therapy. - cardiovascular diseases (including high blood pressure requiring drug treatment), liver disease, chronic kidney disease, endocrine diseases (including diabetes), hemoglobin disease ... - neurological, psychiatric, epilepsy, or guillian-barré disorders. - pathology of hemostasis. - having any surgery for 8 weeks before screening. - history of organ transplantation. - examination and testing results at the time of screening: - systolic pressure above 140 mmhg and/or diastolic pressure over 90mmhg; - systolic blood pressure less than 90 mmhg and/or diastolic pressure below 50 mmhg - real-time nasopharyngeal fluid test - pcr (positive) and/or anti s - igg (positive) with sars-cov-2. - women of potential pregnancy, a positive urine beta-hcg test at the time of screening. - positive with hiv, hepatitis b (hbsag), hepatitis c (anti-hcv) tests - wbc less than 3.5 x 10^9 cells / l - lymphocytes of less than 1.0 x 10^9 cells / l. - neutrophils less than 2.0 x 10^9 cells / l - platelets below 140 x 10^9 cells / l - hb less than 120 g/l for men and less than 100 g/l for women - alt or ast is over 2 times the normal limit - egfr of 90 ml/min/ 1.73m2 or less. - abnormal ecg of clinical significance. - the subject who have taken any drugs or treatments simultaneously and before: - any drug or treatment that affects the immune system such as injectable anti-allergenic drugs, globulin, interferon, immunomodulators, cytotoxic drugs, or any other drug toxic to the body, for 90 days before screening. - systemic steroids (oral or injectable; including intra-articular injection) regardless of dose except for topical form, for 28 days prior to screening. - any vaccine within 28 days prior to screening or planned for in-study vaccination or after 6 months after the first vaccination. - receive or donate blood/serum during the 8 weeks prior to the screening, or plan to receive or donate blood/serum during the study period. - the subject that participated in any clinical trial 28 days prior to the screening date or intends to participate in another clinical study at any point in the study. - women who are pregnant and breastfeeding or planning to become pregnant for the next 6 months from the time of the study 2 vaccines. - the subject has a history of allergy to any of the vaccine components understudying or has a history of at least one past history of allergic or hypersensitivity reactions. - the subject addicted to alcohol (drinking from 5 cups of alcohol daily, glasses of alcohol/can of beer), tobacco/water pipe addicts (smoking from 5 or more cigarettes), drug addiction, opioid dependence - the subject is a member of the research team, sponsor employee, producer (nanogen), and a person related by family (wife, husband, child, father, mother) with those subjects.

- insufficient civil act capacity. - subjects at high risk of sars-cov-2 infection. - subject is/has ever had any acute or chronic medical condition, including but not limited to: - have any inflammatory disease, respiratory tract infection, have any respiratory symptoms such as: cough, sore throat, difficulty breathing, wheezing due to respiratory symptoms within 07 days before screening. fever (armpit temperature ≥ 37°c) for 3 days before vaccination. - history of any chronic respiratory illness such as bronchial asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease (copd). - malignant disease - immune disorders, using immunosuppressive therapy. - cardiovascular diseases (including high blood pressure requiring drug treatment), liver disease, chronic kidney disease, endocrine diseases (including diabetes), hemoglobin disease ... - neurological, psychiatric, epilepsy, or guillian-barré disorders. - pathology of hemostasis. - having any surgery for 8 weeks before screening. - history of organ transplantation. - examination and testing results at the time of screening: - systolic pressure above 140 mmhg and/or diastolic pressure over 90mmhg; - systolic blood pressure less than 90 mmhg and/or diastolic pressure below 50 mmhg - real-time nasopharyngeal fluid test - pcr (positive) and/or anti s - igg (positive) with sars-cov-2. - women of potential pregnancy, a positive urine beta-hcg test at the time of screening. - positive with hiv, hepatitis b (hbsag), hepatitis c (anti-hcv) tests - wbc less than 3.5 x 10^9 cells / l - lymphocytes of less than 1.0 x 10^9 cells / l. - neutrophils less than 2.0 x 10^9 cells / l - platelets below 140 x 10^9 cells / l - hb less than 120 g/l for men and less than 100 g/l for women - alt or ast is over 2 times the normal limit - egfr of 90 ml/min/ 1.73m2 or less. - abnormal ecg of clinical significance. - the subject who have taken any drugs or treatments simultaneously and before: - any drug or treatment that affects the immune system such as injectable anti-allergenic drugs, globulin, interferon, immunomodulators, cytotoxic drugs, or any other drug toxic to the body, for 90 days before screening. - systemic steroids (oral or injectable; including intra-articular injection) regardless of dose except for topical form, for 28 days prior to screening. - any vaccine within 28 days prior to screening or planned for in-study vaccination or after 6 months after the first vaccination. - receive or donate blood/serum during the 8 weeks prior to the screening, or plan to receive or donate blood/serum during the study period. - the subject that participated in any clinical trial 28 days prior to the screening date or intends to participate in another clinical study at any point in the study. - women who are pregnant and breastfeeding or planning to become pregnant for the next 6 months from the time of the study 2 vaccines. - the subject has a history of allergy to any of the vaccine components understudying or has a history of at least one past history of allergic or hypersensitivity reactions. - the subject addicted to alcohol (drinking from 5 cups of alcohol daily, glasses of alcohol/can of beer), tobacco/water pipe addicts (smoking from 5 or more cigarettes), drug addiction, opioid dependence - the subject is a member of the research team, sponsor employee, producer (nanogen), and a person related by family (wife, husband, child, father, mother) with those subjects.